Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review

Pathology Research and Practice

Volumn 211, Issue 8, 2015, Pages 557-569

  Cao, Hui ^a,b   Xu, Enping ^a,b   Liu, Hong ^a,c   Wan, Ledong ^a,b   Lai, Maode ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Key Laboratory of Neuroscience   (China)

^c ZHEJIANG NORMAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Epithelial mesenchymal transition; Malignant phenotypes; Metastasis; Molecular related network

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; FLUOROURACIL; FOLINATE CALCIUM; METHOTREXATE; MICRORNA 141; MICRORNA 200; MICRORNA 200C; MICRORNA 34A; NAVELBINE; OXALIPLATIN; RAPAMYCIN; SALINOMYCIN; SMAD PROTEIN; SMAD4 PROTEIN; STAUROSPORINE; TANESPIMYCIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UNTRANSLATED RNA; UVOMORULIN; VIMENTIN; WNT PROTEIN;

CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); COLON METASTASIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; ONCOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TRANSCRIPTION REGULATION; TUMOR BUDDING; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; CELL MOTION; COLORECTAL TUMOR; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL MOVEMENT; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84983094062     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.05.010     Document Type: Review

References (201)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Cespedes M.V., et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22:571-584.
3. Brenner H., Kloor M., Pox C.P. Colorectal cancer. Lancet 2013.
4. Manfredi S., Lepage C., Hatem C., Coatmeur O., Faivre J., Bouvier A.M. Epidemiology and management of liver metastases from colorectal cancer. Ann. Surg. 2006, 244:254-259.
5. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
6. Boyer B., Thiery J.P. Epithelium-mesenchyme interconversion as example of epithelial plasticity. APMIS 1993, 101:257-268.
7. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
8. Burgess D.J. Breast cancer: circulating and dynamic EMT. Nat. Rev. Cancer 2013, 13:148.
9. Mak P., Leav I., Pursell B., Bae D., Yang X., Taglienti C.A., et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010, 17:319-332.
10. Zhu W., Cai M.Y., Tong Z.T., Dong S.S., Mai S.J., Liao Y.J., et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymal transition. Gut 2012, 61:562-575.
11. Pena C., Garcia J.M., Silva J., Garcia V., Rodriguez R., Alonso I., et al. E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Hum. Mol. Genet. 2005, 14:3361-3370.
12. He X., Chen Z., Jia M., Zhao X. Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLOS ONE 2013, 8:e70858.
13. Hay E.D. An overview of epithelio-mesenchymal transformation. Acta Anat. (Basel) 1995, 154:8-20.
14. Vincent-Salomon A., Thiery J.P. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 2003, 5:101-106.
15. Toiyama Y., Yasuda H., Saigusa S., Tanaka K., Inoue Y., Goel A., et al. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis 2013, 34:2548-2557.
16. Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J., et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2000, 2:84-89.
17. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., Del Barrio M.G., et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2:76-83.
18. Hajra K.M., Chen D.Y., Fearon E.R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002, 62:1613-1618.
19. Comijn J., Berx G., Vermassen P., Verschueren K., Van Grunsven L., Bruyneel E., et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 2001, 7:1267-1278.
20. Eger A., Aigner K., Sonderegger S., Dampier B., Oehler S., Schreiber M., et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005, 24:2375-2385.
21. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
22. Fang X., Cai Y., Liu J., Wang Z., Wu Q., Zhang Z., et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 2011, 30:4707-4720.
23. Perez-Moreno M.A., Locascio A., Rodrigo I., Dhondt G., Portillo F., Nieto M.A., et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J. Biol. Chem. 2001, 276:27424-27431.
24. Kroepil F., Fluegen G., Vallbohmer D., Baldus S.E., Dizdar L., Raffel A.M., et al. Snail1 expression in colorectal cancer and its correlation with clinical and pathological parameters. BMC Cancer 2013, 13:145.
25. Shioiri M., Shida T., Koda K., Oda K., Seike K., Nishimura M., et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br. J. Cancer 2006, 94:1816-1822.
26. Larriba M.J., Martin-Villar E., Garcia J.M., Pereira F., Pena C., De Herreros A.G., et al. Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis 2009, 30:1459-1468.
27. Gomez I., Pena C., Herrera M., Munoz C., Larriba M.J., Garcia V., et al. TWIST1 is expressed in colorectal carcinomas and predicts patient survival. PLoS ONE 2011, 6:e18023.
28. Singh A.B., Sharma A., Smith J.J., Krishnan M., Chen X., Eschrich S., et al. Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology 2011, 141:2140-2153.
29. Spaderna S., Schmalhofer O., Hlubek F., Berx G., Eger A., Merkel S., et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006, 131:830-840.
30. Kahlert C., Lahes S., Radhakrishnan P., Dutta S., Mogler C., Herpel E., et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin. Cancer Res. 2011, 17:7654-7663.
31. Sanchez-Tillo E., De Barrios O., Siles L., Amendola P.G., Darling D.S., Cuatrecasas M., et al. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1. Clin. Cancer Res. 2013, 19:1071-1082.
32. Welch-Reardon K.M., Ehsan S.M., Wang K., Wu N., Newman A.C., Romero-Lopez M., et al. Angiogenic sprouting is regulated by endothelial cell expression of Slug. J. Cell Sci. 2014, 127:2017-2028.
33. Celesti G., Di Caro G., Bianchi P., Grizzi F., Basso G., Marchesi F., et al. Presence of Twist1-positive neoplastic cells in the stroma of chromosome-unstable colorectal tumors. Gastroenterology 2013, 145:647-657. e615.
34. Valdes-Mora F., Gomez Del Pulgar T., Bandres E., Cejas P., Ramirez De Molina A., Perez-Palacios R., et al. TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann. Surg. Oncol. 2009, 16:78-87.
35. Okada T., Suehiro Y., Ueno K., Mitomori S., Kaneko S., Nishioka M., et al. TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer 2010, 49:452-462.
36. Kilic N., Feldhaus S., Kilic E., Tennstedt P., Wicklein D., Wasielewski R., et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur. J. Cancer 2011, 47:1080-1085.
37. Sarkar D., Shields B., Davies M.L., Muller J., Wakeman J.A. BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. Int. J. Cancer 2012, 130:328-337.
38. Jackstadt R., Roh S., Neumann J., Jung P., Hoffmann R., Horst D., et al. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J. Exp. Med. 2013, 210:1331-1350.
39. Mani S.A., Yang J., Brooks M., Schwaninger G., Zhou A., Miura N., et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10069-10074.
40. Watanabe T., Kobunai T., Yamamoto Y., Matsuda K., Ishihara S., Nozawa K., et al. Gene expression of mesenchyme forkhead 1 (FOXC2) significantly correlates with the degree of lymph node metastasis in colorectal cancer. Int. Surg. 2011, 96:207-216.
41. Sanchez-Tillo E., De Barrios O., Siles L., Cuatrecasas M., Castells A., Postigo A. Beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19204-19209.
42. Han X., Fang X., Lou X., Hua D., Ding W., Foltz G., et al. Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. PLoS ONE 2012, 7:e41335.
43. Dai X., Ge J., Wang X., Qian X., Zhang C., Li X. OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncol. Rep. 2013, 29:155-160.
44. Meng H.M., Zheng P., Wang X.Y., Liu C., Sui H.M., Wu S.J., et al. Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol. Ther. 2010, 9:295-302.
45. Lu M.H., Huang C.C., Pan M.R., Chen H.H., Hung W.C. Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clin. Cancer Res. 2012, 18:6416-6425.
46. Ono H., Imoto I., Kozaki K., Tsuda H., Matsui T., Kurasawa Y., et al. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. Oncogene 2012, 31:4923-4934.
47. Takahashi Y., Sawada G., Kurashige J., Uchi R., Matsumura T., Ueo H., et al. Paired related homoeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer. Br. J. Cancer 2013, 109:307-311.
48. Belton A., Gabrovsky A., Bae Y.K., Reeves R., Iacobuzio-Donahue C., Huso D.L., et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS ONE 2012, 7:e30034.
49. Diesch J., Sanij E., Gilan O., Love C., Tran H., Fleming N.I., et al. Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS ONE 2014, 9:e88950.
50. Hahn S., Jackstadt R., Siemens H., Hunten S., Hermeking H. SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. EMBO J. 2013, 32:3079-3095.
51. Zhang W., Jiang B., Guo Z., Sardet C., Zou B., Lam C.S., et al. Four-and-a-half LIM protein 2 promotes invasive potential and epithelial-mesenchymal transition in colon cancer. Carcinogenesis 2010, 31:1220-1229.
52. Zhang W., Wang J., Zou B., Sardet C., Li J., Lam C.S., et al. Four and a half LIM protein 2 (FHL2) negatively regulates the transcription of E-cadherin through interaction with Snail1. Eur. J. Cancer 2011, 47:121-130.
53. Nam E.H., Lee Y., Park Y.K., Lee J.W., Kim S. ZEB2 upregulates integrin alpha5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis 2012, 33:563-571.
54. Nam E.H., Lee Y., Zhao X.F., Park Y.K., Lee J.W., Kim S. ZEB2-Sp1 cooperation induces invasion by upregulating cadherin-11 and integrin alpha5 expression. Carcinogenesis 2014, 35:302-314.
55. Sanchez-Tillo E., Lazaro A., Torrent R., Cuatrecasas M., Vaquero E.C., Castells A., et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010, 29:3490-3500.
56. Li X.L., Hara T., Choi Y., Subramanian M., Francis P., Bilke S., et al. A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster. Mol. Cell. Biol. 2014, 34:533-550.
57. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
58. Matsuzaki K., Seki T., Okazaki K. TGF-beta during human colorectal carcinogenesis: the shift from epithelial to mesenchymal signaling. Inflammopharmacology 2006, 14:198-203.
59. Lampropoulos P., Zizi-Sermpetzoglou A., Rizos S., Kostakis A., Nikiteas N., Papavassiliou A.G. TGF-beta signalling in colon carcinogenesis. Cancer Lett. 2012, 314:1-7.
60. Massague J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 2000, 1:169-178.
61. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
62. Brown K.A., Pietenpol J.A., Moses H.L. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J. Cell. Biochem. 2007, 101:9-33.
63. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
64. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361:2449-2460.
65. Reinacher-Schick A., Baldus S.E., Romdhana B., Landsberg S., Zapatka M., Monig S.P., et al. Loss of Smad4 correlates with loss of the invasion suppressor E-cadherin in advanced colorectal carcinomas. J. Pathol. 2004, 202:412-420.
66. Freeman T.J., Smith J.J., Chen X., Washington M.K., Roland J.T., Means A.L., et al. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Gastroenterology 2012, 142:562-571. e562.
67. Zhang B., Halder S.K., Kashikar N.D., Cho Y.J., Datta A., Gorden D.L., et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology 2010, 138:969-980. e961-e963.
68. Papageorgis P., Cheng K., Ozturk S., Gong Y., Lambert A.W., Abdolmaleky H.M., et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011, 71:998-1008.
69. Pohl M., Radacz Y., Pawlik N., Schoeneck A., Baldus S.E., Munding J., et al. SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells. Anticancer Res. 2010, 30:2603-2613.
70. Zhao S., Venkatasubbarao K., Lazor J.W., Sperry J., Jin C., Cao L., et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res. 2008, 68:4221-4228.
71. Xiong H., Hong J., Du W., Lin Y.W., Ren L.L., Wang Y.C., et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem. 2012, 287:5819-5832.
72. Losi L., Bouzourene H., Benhattar J. Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol. Rep. 2007, 17:1095-1099.
73. Voorneveld P.W., Kodach L.L., Jacobs R.J., Liv N., Zonnevylle A.C., Hoogenboom J.P., et al. Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology 2014, 147:196-208. e113.
74. Hirakawa M., Takimoto R., Tamura F., Yoshida M., Ono M., Murase K., et al. Fucosylated TGF-beta receptors transduces a signal for epithelial-mesenchymal transition in colorectal cancer cells. Br. J. Cancer 2014, 110:156-163.
75. Vincan E., Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin. Exp. Metastasis 2008, 25:657-663.
76. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
77. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10356-10361.
78. Brabletz T., Hlubek F., Spaderna S., Schmalhofer O., Hiendlmeyer E., Jung A., et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005, 179:56-65.
79. Qi L., Sun B., Liu Z., Li H., Gao J., Leng X. Dickkopf-1 inhibits epithelial-mesenchymal transition of colon cancer cells and contributes to colon cancer suppression. Cancer Sci. 2012, 103:828-835.
80. Wu Z.Q., Brabletz T., Fearon E., Willis A.L., Hu C.Y., Li X.Y., et al. Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11312-11317.
81. Stemmer V., De Craene B., Berx G., Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene 2008, 27:5075-5080.
82. Pelaez I.M., Kalogeropoulou M., Ferraro A., Voulgari A., Pankotai T., Boros I., et al. Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells. Int. J. Biochem. Cell Biol. 2010, 42:911-920.
83. Wang Y., Ngo V.N., Marani M., Yang Y., Wright G., Staudt L.M., et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010, 29:4658-4670.
84. Makrodouli E., Oikonomou E., Koc M., Andera L., Sasazuki T., Shirasawa S., et al. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol. Cancer 2011, 10:118.
85. Lemieux S., Bergeron V., Durand C., Asselin C., Saucier N., Rivard Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. Int. J. Cancer 2009, 125:1575-1586.
86. Ferraro A., Mourtzoukou D., Kosmidou V., Avlonitis S., Kontogeorgos G., Zografos G., et al. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control epithelial-mesenchymal transition and anoikis in colon cancer cells. Int. J. Biochem. Cell Biol. 2013, 45:243-254.
87. Koelzer V.H., Karamitopoulou E., Dawson H., Kondi-Pafiti A., Zlobec I., Lugli A. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br. J. Cancer 2013, 108:2088-2096.
88. Li X., Stevens P.D., Liu J., Yang H., Wang W., Wang C., et al. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology 2014, 146:1301-1312. e1301-e1310.
89. Roy H.K., Olusola B.F., Clemens D.L., Karolski W.J., Ratashak A., Lynch H.T., et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002, 23:201-205.
90. Suman S., Kurisetty V., Das T.P., Vadodkar A., Ramos G., Lakshmanaswamy R., et al. Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells. Mol. Carcinog. 2014, 53(Suppl. 1):E151-E160.
91. Wang H., Quah S.Y., Dong J.M., Manser E., Tang J.P., Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007, 67:2922-2926.
92. Gulhati P., Bowen K.A., Liu J., Stevens P.D., Rychahou P.G., Chen M., et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011, 71:3246-3256.
93. Katoh M., Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol. Ther. 2006, 5:1059-1064.
94. Slattery M.L., Potter J.D., Duncan D.M., Berry T.D. Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. Int. J. Cancer 1997, 73:670-677.
95. Tang F.Y., Pai M.H., Chiang E.P. Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model. J. Nutr. Biochem. 2012, 23:1302-1313.
96. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2999-3004.
97. Hurteau G.J., Carlson J.A., Spivack S.D., Brock G.J. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67:7972-7976.
98. Christoffersen N.R., Silahtaroglu A., Orom U.A., Kauppinen S., Lund A.H. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA 2007, 13:1172-1178.
99. Chen M.L., Liang L.S., Wang X.K. miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1. Clin. Exp. Metastasis 2012, 29:457-469.
100. Chang C.J., Chao C.H., Xia W., Yang J.Y., Xiong Y., Li C.W., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 13:317-323.
101. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
102. Hur K., Toiyama Y., Takahashi M., Balaguer F., Nagasaka T., Koike J., et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013, 62:1315-1326.
103. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
104. Davalos V., Moutinho C., Villanueva A., Boque R., Silva P., Carneiro F., et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012, 31:2062-2074.
105. Paterson E.L., Kazenwadel J., Bert A.G., Khew-Goodall Y., Ruszkiewicz A., Goodall G.J. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 2013, 15:180-191.
106. Bojmar L., Karlsson E., Ellegard S., Olsson H., Bjornsson B., Hallbook O., et al. The role of microRNA-200 in progression of human colorectal and breast cancer. PLOS ONE 2013, 8:e84815.
107. Pichler M., Ress A.L., Winter E., Stiegelbauer V., Karbiener M., Schwarzenbacher D., et al. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. Br. J. Cancer 2014, 110:1614-1621.
108. Wu J., Wu G., Lv L., Ren Y.F., Zhang X.J., Xue Y.F., et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis 2012, 33:519-528.
109. Siemens H., Neumann J., Jackstadt R., Mansmann U., Horst D., Kirchner T., et al. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. Clin. Cancer Res. 2013, 19:710-720.
110. Siemens H., Jackstadt R., Hunten S., Kaller M., Menssen A., Gotz U., et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011, 10:4256-4271.
111. Rokavec M., Oner M.G., Li H., Jackstadt R., Jiang L., Lodygin D., et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 2014, 124:1853-1867.
112. Shi L., Jackstadt R., Siemens H., Li H., Kirchner T., Hermeking H. p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 2014, 74:532-542.
113. Han H.B., Gu J., Zuo H.J., Chen Z.G., Zhao W., Li M., et al. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J. Pathol. 2012, 226:544-555.
114. Liang L., Li X., Zhang X., Lv Z., He G., Zhao W., et al. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2. Gastroenterology 2013, 144:624-635. e624.
115. Li Y., Zhu X., Zeng Y., Wang J., Zhang X., Ding Y.Q., et al. FMNL2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition. Mol. Cancer Res. 2010, 8:1579-1590.
116. Long L., Huang G., Zhu H., Guo Y., Liu Y., Huo J. Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2. J. Transl. Med. 2013, 11:275.
117. Meng X., Wu J., Pan C., Wang H., Ying X., Zhou Y., et al. Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD. Gastroenterology 2013, 145:426-436. e421-e426.
118. Zhao H., Xu Z., Qin H., Gao Z., Gao L. miR-30b regulates migration and invasion of human colorectal cancer via SIX1. Biochem. J. 2014, 460:117-125.
119. Zhao H., Dong T., Zhou H., Wang L., Huang A., Feng B., et al. miR-320a suppresses colorectal cancer progression by targeting Rac1. Carcinogenesis 2014, 35:886-895.
120. Strillacci A., Valerii M.C., Sansone P., Caggiano C., Sgromo A., Vittori L., et al. Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J. Pathol. 2013, 229:379-389.
121. Pizzini S., Bisognin A., Mandruzzato S., Biasiolo M., Facciolli A., Perilli L., et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics 2013, 14:589.
122. Cottonham C.L., Kaneko S., Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J. Biol. Chem. 2010, 285:35293-35302.
123. Ferraro A., Kontos C.K., Boni T., Bantounas I., Siakouli D., Kosmidou V., et al. Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGBeta4-PDCD4) as predictor of metastatic tumor potential. Epigenetics 2014, 9:129-141.
124. Liu G.H., Zhou Z.G., Chen R., Wang M.J., Zhou B., Li Y., et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013, 34:2175-2181.
125. Xia X., Yang B., Zhai X., Liu X., Shen K., Wu Z., et al. Prognostic role of microRNA-21 in colorectal cancer: a meta-analysis. PLOS ONE 2013, 8:e80426.
126. Yang M.H., Yu J., Chen N., Wang X.Y., Liu X.Y., Wang S., et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLOS ONE 2013, 8:e85353.
127. Colangelo T., Fucci A., Votino C., Sabatino L., Pancione M., Laudanna C., et al. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia 2013, 15:1218-1231.
128. Tang W., Zhu Y., Gao J., Fu J., Liu C., Liu Y., et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br. J. Cancer 2014, 110:450-458.
129. Chen H.Y., Lin Y.M., Chung H.C., Lang Y.D., Lin C.J., Huang J., et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 2012, 72:3631-3641.
130. Orom U.A., Derrien T., Beringer M., Gumireddy K., Gardini A., Bussotti G., et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010, 143:46-58.
131. Padua Alves C., Fonseca A.S., Muys B.R., De Barros E.L.B.R., Burger M.C., De Souza J.E., et al. Brief report: the lincRNA hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells 2013, 31:2827-2832.
132. Fan Y., Shen B., Tan M., Mu X., Qin Y., Zhang F., et al. TGF-beta-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin. Cancer Res. 2014, 20:1531-1541.
133. Yuan J.H., Yang F., Wang F., Ma J.Z., Guo Y.J., Tao Q.F., et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014, 25:666-681.
134. Karagiannis G.S., Poutahidis T., Erdman S.E., Kirsch R., Riddell R.H., Diamandis E.P. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol. Cancer Res. 2012, 10:1403-1418.
135. Herrera M., Islam A.B., Herrera A., Martin P., Garcia V., Silva J., et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin. Cancer Res. 2013, 19:5914-5926.
136. Karagiannis G.S., Petraki C., Prassas I., Saraon P., Musrap N., Dimitromanolakis A., et al. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget 2012, 3:267-285.
137. Rupp C., Scherzer M., Rudisch A., Unger C., Haslinger C., Schweifer N., et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. Oncogene 2015, 34:815-825.
138. Zhu S., Zhang J., Xu F., Xu E., Ruan W., Ma Y., et al. IGFBP-rP1 suppresses epithelial-mesenchymal transition and metastasis in colorectal cancer. Cell Death Dis. 2015, 6:e1695.
139. Jensen S.A., Vainer B., Bartels A., Brunner N., Sorensen J.B. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells - associations with histopathology and patients outcome. Eur. J. Cancer 2010, 46:3233-3242.
140. Li Y., Wang L., Pappan L., Galliher-Beckley A., Shi J. IL-1beta promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol. Cancer 2012, 11:87.
141. Cheng X.S., Li Y.F., Tan J., Sun B., Xiao Y.C., Fang X.B., et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett. 2014, 348:77-87.
142. Matsumoto S., Hara T., Mitsuyama K., Yamamoto M., Tsuruta O., Sata M., et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol. 2010, 184:1543-1551.
143. Brighenti E., Calabrese C., Liguori G., Giannone F.A., Trere D., Montanaro L., et al. Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer. Oncogene 2014, 33:4396-4406.
144. Liu H., Ren G., Wang T., Chen Y., Gong C., Bai Y., et al. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition. Carcinogenesis 2015, 36:459-468.
145. Chellappan S.P., Wang H., Wang H.-S., Zhou B.-H., Li C.-L., Zhang F., et al. Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer. PLOS ONE 2013, 8:e56664.
146. Bates R.C., Deleo M.J., Mercurio 3rd A.M. The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp. Cell Res. 2004, 299:315-324.
147. Torres S., Bartolome R.A., Mendes M., Barderas R., Fernandez-Acenero M.J., Pelaez-Garcia A., et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin. Cancer Res. 2013, 19:6006-6019.
148. Herrera A., Herrera M., Alba-Castellon L., Silva J., Garcia V., Loubat-Casanovas J., et al. Protumorigenic effects of Snail-expression fibroblasts on colon cancer cells. Int. J. Cancer 2014, 134:2984-2990.
149. Hwang W.L., Yang M.H., Tsai M.L., Lan H.Y., Su S.H., Chang S.C., et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011, 141:279-291. 291 e271-e275.
150. Zeng X., Yang P., Chen B., Jin X., Liu Y., Zhao X., et al. Quantitative secretome analysis reveals the interactions between epithelia and tumor cells by in vitro modulating colon cancer microenvironment. J. Proteom. 2013, 89:51-70.
151. Itatani Y., Kawada K., Fujishita T., Kakizaki F., Hirai H., Matsumoto T., et al. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. Gastroenterology 2013, 145:1064-1075. e1011.
152. Kitamura T., Fujishita T., Loetscher P., Revesz L., Hashida H., Kizaka-Kondoh S., et al. Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13063-13068.
153. Mele V., Muraro M.G., Calabrese D., Pfaff D., Amatruda N., Amicarella F., et al. Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-beta. Int. J. Cancer 2014, 134:2583-2594.
154. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11:123-134.
155. Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20:576-590.
156. Steller E.J., Raats D.A., Koster J., Rutten B., Govaert K.M., Emmink B.L., et al. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia 2013, 15:204-217.
157. Ou J., Peng Y., Deng J., Miao H., Zhou J., Zha L., et al. Endothelial cell-derived-fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial-mesenchymal transition. Carcinogenesis 2014, 35:1661-1670.
158. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007, 50:151-162.
159. Ueno H., Murphy J., Jass J.R., Mochizuki H., Talbot I.C. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002, 40:127-132.
160. Hase K., Shatney C., Johnson D., Trollope M., Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis. Colon Rectum 1993, 36:627-635.
161. Nakamura T., Mitomi H., Kikuchi S., Ohtani Y., Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology 2005, 52:1432-1435.
162. Wang L.M., Kevans D., Mulcahy H., O'sullivan J., Fennelly D., Hyland J., et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am. J. Surg. Pathol. 2009, 33:134-141.
163. Tanaka M., Hashiguchi Y., Ueno H., Hase K., Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis. Colon Rectum 2003, 46:1054-1059.
164. Prall F., Nizze H., Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 2005, 47:17-24.
165. C. Compton, Prognostic Factors in Cancer. 3rd edn. Wiley-Liss, New York. 2006.
166. Kirchner T., Brabletz T. Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am. J. Pathol. 2000, 157:1113-1121.
167. Khanh D.T., Mekata E., Mukaisho K.-I., Sugihara H., Shimizu T., Shiomi H., et al. Prognostic role of CD10+ myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci. 2011, 102:1724-1733.
168. Oshiro R., Yamamoto H., Takahashi H., Ohtsuka M., Wu X., Nishimura J., et al. C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer. Cancer Sci. 2012, 103:1155-1164.
169. Guzinska-Ustymowicz K. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res. 2006, 26:1589-1594.
170. Markl B., Renk I., Oruzio D.V., Jahnig H., Schenkirsch G., Scholer C., et al. Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. J. Surg. Oncol. 2010, 102:235-241.
171. Masaki T., Sugiyama M., Matsuoka H., Abe N., Izumisato Y., Sakamoto A., et al. Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomas. Dig. Dis. Sci. 2003, 48:1262-1267.
172. Zlobec I., Lugli A. Epithelial-mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010, 1:651-661.
173. Yang A.D. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 2006, 12:4147-4153.
174. Zheng H.X., Cai Y.D., Wang Y.D., Cui X.B., Xie T.T., Li W.J., et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 2013, 32:1183-1192.
175. Hoshino H., Miyoshi N., Nagai K., Tomimaru Y., Nagano H., Sekimoto M., et al. Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Biochem. Biophys. Res. Commun. 2009, 390:1061-1065.
176. Findlay V.J., Moretz R.E., Wang C., Vaena S.G., Bandurraga S.G., Ashenafi M., et al. Slug expression inhibits calcitriol-mediated sensitivity to radiation in colorectal cancer. Mol. Carcinog. 2014, 53(Suppl. 1):E130-E139.
177. Albasri A., Seth R., Jackson D., Benhasouna A., Crook S., Nateri A.S., et al. C-terminal Tensin-like (CTEN) is an oncogene which alters cell motility possibly through repression of E-cadherin in colorectal cancer. J. Pathol. 2009, 218:57-65.
178. Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther. 2009, 8:1055-1066.
179. Chen X., Wang Y., Xia H., Wang Q., Jiang X., Lin Z., et al. Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis. Mol. Biol. Rep. 2012, 39:6707-6714.
180. Kawamoto A., Yokoe T., Tanaka K., Saigusa S., Toiyama Y., Yasuda H., et al. Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol. Rep. 2012, 27:51-57.
181. Kudo-Saito C., Shirako H., Takeuchi T., Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009, 15:195-206.
182. Buck E., Eyzaguirre A., Barr S., Thompson S., Sennello R., Young D., et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 2007, 6:532-541.
183. Trumpp A., Wiestler O.D. Mechanisms of disease: cancer stem cells - targeting the evil twin. Nat. Clin. Pract. Oncol. 2008, 5:337-347.
184. Fan C.W., Chen T., Shang Y.N., Gu Y.Z., Zhang S.L., Lu R., et al. Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies. Cell Death Dis. 2013, 4:e828.
185. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
186. Hirano T., Satow R., Kato A., Tamura M., Murayama Y., Saya H., et al. Identification of novel small compounds that restore E-cadherin expression and inhibit tumor cell motility and invasiveness. Biochem. Pharmacol. 2013, 86:1419-1429.
187. Fernando R.I., Litzinger M., Trono P., Hamilton D.H., Schlom J., Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J. Clin. Invest. 2010, 120:533-544.
188. Roselli M., Fernando R.I., Guadagni F., Spila A., Alessandroni J., Palmirotta R., et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin. Cancer Res. 2012, 18:3868-3879.
189. Palena C., Polev D.E., Tsang K.Y., Fernando R.I., Litzinger M., Krukovskaya L.L., et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin. Cancer Res. 2007, 13:2471-2478.
190. Hamilton D.H., Litzinger M.T., Jales A., Huang B., Fernando R.I., Hodge J.W., et al. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 2013, 4:1777-1790.
191. Ardiani A., Gameiro S.R., Palena C., Hamilton D.H., Kwilas A., King T.H., et al. Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. Cancer Res. 2014, 74:1945-1957.
192. Vidic S., Markelc B., Sersa G., Coer A., Kamensek U., Tevz G., et al. MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Cancer Gene Ther. 2010, 17:409-419.
193. Chua K.N., Sim W.J., Racine V., Lee S.Y., Goh B.C., Thiery J.P. A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLoS ONE 2012, 7:e33183.
194. Flanigan S.A., Pitts T.M., Newton T.P., Kulikowski G.N., Tan A.C., Mcmanus M.C., et al. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin. Cancer Res. 2013, 19:6219-6229.
195. Bocca C., Bozzo F., Cannito S., Parola M., Miglietta A. Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Mol. Carcinog. 2012, 51:783-795.
196. Reka A.K., Kuick R., Kurapati H., Standiford T.J., Omenn G.S., Keshamouni V.G. Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J. Thorac. Oncol. 2011, 6:1784-1792.
197. Zubeldia I.G., Bleau A.M., Redrado M., Serrano D., Agliano A., Gil-Puig C., et al. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFbeta1-targeting peptides P17 and P144. Exp. Cell Res. 2013, 319:12-22.
198. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
199. John Giannios, et al. Inhibition of epithelial-mesenchymal transition (EMT) with immunochemogene treatment in metastatic colorectal cancer. Gastrointest. Cancer Res. 2010, Suppl2:S11.
200. Harouaka R., Kang Z., Zheng S.Y., Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol. Ther. 2014, 141:209-221.
201. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., Mcallister F., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.